The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses longer-term follow-up from the Phase III MANIFEST-2 trial (NCT04603495) evaluating combination therapy in patients with myelofibrosis. He highlights the durability of spleen volume reduction at 96 weeks and the importance of sustained treatment responses beyond the primary 24-week endpoint, with further follow-up expected at 144 weeks. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
